$1.29 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$10.62 - $28.20The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$1.29 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+45.7%|
|Outstanding Shares||84.1 Million|
|Avg 30 Day Volume||829 Thousand|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
Mizuho Securities Stick to Their Buy Rating for Atara BiotherapeuticsInvesting.com, 14 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transform...Business Wire, 4 months ago
Atara Biotherapeutics (NASDAQ:ATRA) announced its quarterly earnings data on Sunday. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estim...Transcript Daily, 4 months ago